Visikol Names Brian Mulhall as Director of Corporate Development
Mike Johnson2019-02-21T01:30:52-05:00Expected to play a key role in the partnership formation for the company’s drug discovery services which leverage their patented [...]
Expected to play a key role in the partnership formation for the company’s drug discovery services which leverage their patented [...]
NEW BRUNSWICK, N.J. (PRWEB) APRIL 15, 2018 For as little as $500 per tissue sample, Visikol is now offering 3D [...]
As a company focused on three-dimensional tissue imaging, digital pathology and advanced in vitro models, we have been very focused [...]
WHITEHOUSE, N.J. (PRWEB) MAY 14, 2018 The move is a key milestone that will enable the company to expand its [...]
WHITEHOUSE, N.J. (PRWEB) JUNE 6, 2018 Recently, Visikol, a contract research organization focused on digital pathology and optical imaging built [...]
The Visikol team is proud to announce that it has secured two SBIR grants from the NIH and NSF for [...]
BASEL, Switzerland and WHITEHOUSE STATION, N.J. /PRWEB/ -- July 5, 2018 Enzyvant, a biopharmaceutical company focused on developing innovative treatments [...]
Visikol CEO and Co-Founder Dr. Michael Johnson was named to the Forbes 30 Under 30 list in 2017 and was [...]
October 26 and 17, 2018 | Sheraton Hotel | Boston, MA 3D cell culture is exploding. To capture the energy [...]
WHITEHOUSE STATION, N.J. (PRWEB) OCTOBER 15, 2018 Since the inception of the microscope, researchers and clinicians have characterized tissues through [...]